Oxytocin/Ergometrine Maleate(Oxytocin/Ergometrine Maleate) - 药物靶点：OXTR x α-adrenergic receptor_在研适应症：产后出血_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Syntometrine

靶点

OXTR x α-adrenergic receptor

作用机制

OXTR激动剂(催产素受体激动剂)、α-adrenergic receptor激动剂(α-肾上腺素能受体家族激动剂)

治疗领域

泌尿生殖系统疾病

在研适应症

产后出血

非在研适应症-

原研机构-

在研机构

Phebra Pty Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

澳大利亚 (1991-08-21),

产后出血

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C66H93N15O18S2

InChIKeyCEDGTLOSFDBJKR-HYFBGPJTSA-N

CAS号37209-62-4

序列信息

Sequence Code 124252

关联

3

项与 Oxytocin/Ergometrine Maleate 相关的临床试验

NCT02046499 / CompletedN/AIIT

A Randomized Trial Comparing Oxytocin and Oxytocin + Ergometrine for Prevention of Postpartum Haemorrhage at Caesarean Section

This is a randomized trial comparing oxytocin versus oxytocin + syntometrine in the prevention of post partum haemorrhage in patients undergoing caesarean section

开始日期2014-01-01

申办/合作机构

University of Pretoria

NCT01236482 / Unknown status临床4期IIT

Comparing Oxytocin and Oxytocin-ergometrine Combinations for Increasing Uterine Tone in Cesarean Delivery: a Pharmacokinetic-pharmacodynamic Study.

In this study the investigators hypothesize that infused combinations of oxytocin and ergometrine will exhibit fewer cardiac and neurological side effects than equipotent infusion of oxytocin alone. In order to perform this study the investigators perform the following steps:
The investigators validate a quantitative measure of uterine tone as our primary endpoint.
The investigators use this endpoint measure in order to determine equipotential doses of different tocotonic drug regimens, based on the ED50 for each.
Using equipontial ratios based on the ED50, the investigators compare hemodynamic and other side effects of these tocotonic drug regimes. Plasma levels of oxytocin will be measured.

开始日期2010-11-01

申办/合作机构

Hadassah University Hospital

NCT00499005 / Completed临床4期IIT

Carbetocin Versus Syntometrine for the Third Stage of Labour Following Vaginal Delivery - A Double-blind Randomised Trial

Intramuscular carbetocin is as effective as intramuscular syntometrine for the prevention of postpartum haemorrhage

开始日期2006-11-01

申办/合作机构

National University Hospital

[+1]

100 项与 Oxytocin/Ergometrine Maleate 相关的临床结果

登录后查看更多信息

100 项与 Oxytocin/Ergometrine Maleate 相关的转化医学

登录后查看更多信息

100 项与 Oxytocin/Ergometrine Maleate 相关的专利（医药）

登录后查看更多信息

88

项与 Oxytocin/Ergometrine Maleate 相关的文献（医药）

2022-12-30·The Journal of Maternal-Fetal & Neonatal Medicine

Expression of Concern: Carbetocin versus syntometrine for prevention of postpartum hemorrhage after cesarean section

Article

2021-06-01·BJOG: An International Journal of Obstetrics & Gynaecology1区 · 医学

Oxytocin: still the optimal prophylactic despite soaring rates of haemorrhage at birth

1区 · 医学

Article

作者: Weeks, AD

The results of the IMox study, although not surprising, are very much to be welcomed.This high-quality, double-blind study provides conclusive evidence that there is essentially no difference in effectiveness between the 3 main i.m. (i.m.) prophylactic uterotonics: oxytocin 10IU.Carbetocin and oxytocin + ergometrine (Syntometrine) (van der Nelson et al. BJOG 2021;128:1236-1246).Blood loss of 500 mL, blood loss of 1000 mL and need for blood transfusion were the same in all three groups.The only difference in effectiveness was that those who received oxytocin + ergometrine needed slightly fewer addnl. uterotonics (16%, vs. 19% in the other two groups) suggesting that this combination was marginally stronger.The price for that, however, was great: those who received oxytocin + ergometrine were far more likely to experience nausea (24%), vomiting (18%) or hypertension (12%), and this led to 8% of women feeling that their ability to bond or care for their baby was affected by adverse effects almost twice the rate with oxytocin or carbetocin.All this confirms what we already believed about i.m. uterotonics for prophylaxis: oxytocin alone is the optimal choice.

2021-06-01·BJOG: An International Journal of Obstetrics & Gynaecology1区 · 医学

Intramuscular oxytocin versus Syntometrine^® versus carbetocin for prevention of primary postpartum haemorrhage after vaginal birth: a randomised double‐blinded clinical trial of effectiveness, side effects and quality of life

1区 · 医学

Article

作者: Burnard, S ; Alvarez, M ; Knowlden, J ; van der Nelson, H ; Marques, E ; Burden, C ; Mayer, M ; Dailami, N ; O'Brien, S ; Siassakos, D ; Draycott, T ; Winter, C

ObjectiveTo compare intramuscular oxytocin, Syntometrine® and carbetocin for prevention of postpartum haemorrhage after vaginal birth.DesignRandomised double‐blinded clinical trial.SettingSix hospitals in England.PopulationA total of 5929 normotensive women having a singleton vaginal birth.MethodsRandomisation when birth was imminent.Main outcome measuresPrimary: use of additional uterotonic agents. Secondary: weighed blood loss, transfusion, manual removal of placenta, adverse effects, quality of life.ResultsParticipants receiving additional uterotonics: 368 (19.5%) oxytocin, 298 (15.6%) Syntometrine and 364 (19.1%) carbetocin. When pairwise comparisons were made: women receiving carbetocin were significantly more likely to receive additional uterotonics than those receiving Syntometrine (odds ratio [OR] 1.28, 95% CI 1.08–1.51, P = 0.004); the difference between carbetocin and oxytocin was non‐significant (P = 0.78); Participants receiving Syntometrine were significantly less likely to receive additional uterotonics than those receiving oxytocin (OR 0.75, 95% CI 0.65–0.91, P = 0.002). Non‐inferiority between carbetocin and Syntometrine was not shown. Use of Syntometrine reduced non‐drug PPH treatments compared with oxytocin (OR 0.64, 95% CI 0.42–0.97) but not carbetocin (P = 0.64). Rates of PPH and blood transfusion were not different. Syntometrine was associated with an increase in maternal adverse effects and reduced ability of the mother to bond with her baby.ConclusionsNon‐inferiority of carbetocin to Syntometrine was not shown. Carbetocin is not significantly different to oxytocin for use of additional uterotonics. Use of Syntometrine reduced use of additional uterotonics and need for non‐drug PPH treatments compared with oxytocin. Increased maternal adverse effects are a disadvantage of Syntometrine.Tweetable abstractIM carbetocin does not reduce additional uterotonic use compared with IM Syntometrine or oxytocin.

100 项与 Oxytocin/Ergometrine Maleate 相关的药物交易

登录后查看更多信息